SCHEMBL10326042

SCHEMBL10326042

CCOC(=O)C1=Cc2cc(-c3cccc(OC)c3)ccc2N=C(N)C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 10/20 0.61
TLR7 Q9NYK1 4/20 0.61
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 4/20 0.43
CSNK1D P48730 1/20 0.43
HPGD P15428 4/20 0.41
HSD17B10 Q99714 4/20 0.41
ALOX15 P16050 1/20 0.41
CACNB4 O00305 2/20 0.41
CACNA1A O00555 2/20 0.41
CACNA1G O43497 2/20 0.41
CACNG3 O60359 2/20 0.41
CACNA1F O60840 2/20 0.41
CACNA1H O95180 2/20 0.41
CACNB3 P54284 2/20 0.41
CACNA2D1 P54289 2/20 0.41
CACNG7 P62955 2/20 0.41
CACNA1B Q00975 2/20 0.41
CACNA1D Q01668 2/20 0.41
CACNB1 Q02641 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326201 0.91 TLR8 (0.56) TLR8TLR7ALDH1A1KDM4EHPGD
SCHEMBL15496644 0.89 TLR8 (0.64) TLR8TLR7
SCHEMBL10345313 0.88 TLR8 (0.67) TLR8TLR7ALDH1A1KDM4EHPGD
SCHEMBL8188956 0.88 TLR8 (0.53) TLR8TLR7ALDH1A1KDM4EHPGD
SCHEMBL27936502 0.86 ALDH1A1 (0.44) TLR8TLR7ALDH1A1HPGDCHEK2
SCHEMBL10325490 0.85 TLR8 (0.59) TLR8TLR7
SCHEMBL10325466 0.84 TLR8 (0.59) TLR8TLR7ALDH1A1KDM4EHPGD
SCHEMBL10325435 0.84 TLR8 (0.59) TLR8TLR7
SCHEMBL10325903 0.84 TLR8 (0.58) TLR8TLR7
SCHEMBL10344974 0.84 TLR8 (0.61) TLR8TLR7ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3208263-A1 SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS VentiRx Pharmaceuticals, Inc. (US) 2017-08-23 EP disclosed
US-9718796-B2 Substituted benzoazepines as toll-like receptor modulators VENTIRX PHARMACEUTICALS, INC. (US) 2017-08-01 US disclosed
US-9718796-B2 Substituted benzoazepines as toll-like receptor modulators VENTIRX PHARMACEUTICALS, INC. (US) 2017-08-01 US disclosed
EP-2663550-B1 SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS VENTIRX PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
EP-2663550-B1 SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS VENTIRX PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
US-20140066432-A1 Substituted Benzoazepines As Toll-Like Receptor Modulators VENTIRX PHARMACEUTICALS, INC. 2014-03-06 US disclosed
US-20140066432-A1 Substituted Benzoazepines As Toll-Like Receptor Modulators VENTIRX PHARMACEUTICALS, INC. 2014-03-06 US disclosed
EP-2663550-A2 SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS VentiRx Pharmaceuticals, Inc. (US) 2013-11-20 EP disclosed
WO-2012097173-A2 SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS VENTIRX PHARMACEUTICALS, INC. (US) 2012-07-19 WO disclosed
WO-2012097173-A2 SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS VENTIRX PHARMACEUTICALS, INC. (US) 2012-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066432-A1 Substituted Benzoazepines As Toll-Like Receptor Modulators TLR8, TLR9, TLR1 TLR8 1/4885TLR7 4/4885ALDH1A1 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.